MarketCap
Facebook
X
TelegramAnnual report 2025
added 04-01-2026
China Pharma Holdings Long-Term Debt 2011-2026 | CPHI
Long-term debt is a financial obligation of a company or an individual with a repayment period exceeding one year from the date it arises. In accounting, such obligations are recorded under the "long-term liabilities" section.
Main characteristics:- Term exceeds 12 months
- Can take the form of bonds, bank loans, credit lines, leasing, or loans from affiliated parties
- Repaid through regular payments (interest and/or principal) over several years
- Investment in development
Allows financing of large projects — new factories, production lines, innovative developments — without diverting working capital. - Smoothing of cash flows
A long-term payment schedule facilitates budget planning and reduces short-term financial risks. - Optimization of capital structure
A combination of equity and borrowed capital can reduce the average cost of business financing.
A high level of long-term debt may indicate that a company heavily relies on borrowed funds. This increases risks, especially in conditions of rising interest rates or declining profits. However, a moderate level of debt can signal a sound growth strategy — for example, the company takes a loan to expand its business.
If a company uses borrowed funds effectively (e.g., invests in profitable projects), this can lead to profit growth and, consequently, an increase in stock value. An investor evaluates whether the investments made using debt are paying off.
It is important to monitor whether the company can regularly pay interest and repay the principal. Payment difficulties can lead to reduced dividends, a drop in stock value, and even bankruptcy.
Examples of long-term debt:- Mortgage loans for property purchases
- Corporate bonds issued by a company to raise capital
- Project financing — long-term loans for building or expanding production facilities
- Leasing obligations for equipment or transport
Annual Long-Term Debt China Pharma Holdings
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 112 K | - | 39.9 K | - | 44.2 K | 904 K | 2.15 M | 4.36 M | 6.92 M | 8.64 M | 10.8 M | 11.4 M | 12.5 M | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 12.5 M | 39.9 K | 5.26 M |
Quarterly Long-Term Debt China Pharma Holdings
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 128 K | - | - | - | - | - | - | 39.9 K | 58.8 K | 77.6 K | - | - | - | - | 22.3 K | 44.2 K | 4.33 M | 5.02 M | 5.01 M | 5.24 M | 4.97 M | 6 M | 4.09 M | 4.3 M | 4.24 M | 6.4 M | 6.56 M | 6.54 M | 6.55 M | 8.91 M | 9.39 M | 9.22 M | 9.17 M | 10.2 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 10.2 M | 22.3 K | 4.85 M |
Long-Term Debt of other stocks in the Drug manufacturers industry
| Issuer | Long-Term Debt | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
AcelRx Pharmaceuticals
ACRX
|
5.01 M | - | 7.5 % | $ 6.35 M |  USA |
 |
Cronos Group
CRON
|
4.27 M | $ 2.58 | 1.98 % | $ 1.37 B |  Canada |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
343 K | - | 0.86 % | $ 117 M | USA |
 |
Aerie Pharmaceuticals
AERI
|
21.8 M | - | - | $ 754 M | USA |
 |
Assertio Holdings
ASRT
|
39.1 M | $ 19.26 | 0.26 % | $ 123 M | USA |
 |
Agile Therapeutics
AGRX
|
1.52 M | - | 10.11 % | $ 58.2 M | USA |
 |
Alimera Sciences
ALIM
|
256 K | - | - | $ 142 M | USA |
 |
Athenex
ATNX
|
93 K | - | -23.39 % | $ 1.76 M | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
1.12 M | - | - | $ 2.06 B |  France |
 |
Calliditas Therapeutics AB (publ)
CALT
|
24.1 M | - | -0.1 % | $ 2.03 B |  Schweden |
 |
HEXO Corp.
HEXO
|
29 M | - | 2.45 % | $ 38.1 M | Canada |
 |
Bausch Health Companies
BHC
|
21.9 B | $ 5.41 | 1.12 % | $ 1.97 B | Canada |
 |
OrganiGram Holdings
OGI
|
104 M | $ 1.38 | - | $ 402 M | Canada |
 |
Aurora Cannabis
ACB
|
295 M | $ 3.44 | - | $ 86.3 M | Canada |
 |
Canopy Growth Corporation
CGC
|
300 M | $ 1.02 | 2.0 % | $ 110 M | Canada |
 |
Cumberland Pharmaceuticals
CPIX
|
4.94 M | $ 3.1 | -2.21 % | $ 43.6 M | USA |
 |
Catalent
CTLT
|
4.86 B | - | - | $ 11.5 B | USA |
 |
DURECT Corporation
DRRX
|
16.7 M | - | - | $ 50.1 M | USA |
 |
Eagle Pharmaceuticals
EGRX
|
56.2 M | - | -39.89 % | $ 27.7 M | USA |
 |
Endo International plc
ENDP
|
8.15 B | - | - | $ 28.9 M |  Irlanda |
 |
Evolus
EOLS
|
146 M | $ 4.16 | 3.23 % | $ 268 M | USA |
 |
Emergent BioSolutions
EBS
|
446 M | $ 8.1 | -1.58 % | $ 415 M | USA |
 |
Evoke Pharma
EVOK
|
5 M | - | - | $ 36.6 M | USA |
 |
Harrow Health
HROW
|
250 M | $ 35.13 | -0.51 % | $ 1.29 B | USA |
 |
Jupiter Wellness
JUPW
|
114 K | - | - | $ 33.6 M | USA |
 |
Lannett Company
LCI
|
615 M | - | 1.15 % | $ 7.11 M | USA |
 |
Neoleukin Therapeutics
NLTX
|
5 K | - | - | $ 193 M | Canada |
 |
OptiNose
OPTN
|
611 K | - | - | $ 1.08 B | USA |
 |
Organogenesis Holdings
ORGO
|
718 K | $ 2.24 | - | $ 295 M | USA |
 |
Pacira BioSciences
PCRX
|
585 M | $ 22.27 | -1.89 % | $ 1.03 B | USA |
 |
PetIQ
PETQ
|
438 M | - | 1.64 % | $ 400 M | USA |
 |
Sundial Growers
SNDL
|
16.2 M | $ 1.34 | -1.47 % | $ 3.37 M | Canada |
 |
PLx Pharma
PLXP
|
622 K | - | -27.8 % | $ 2.56 M | USA |
 |
ProPhase Labs
PRPH
|
2.4 M | - | - | $ 5.07 M | USA |
 |
Radius Health
RDUS
|
315 K | - | - | $ 1.42 B | USA |
 |
Recro Pharma
REPH
|
339 K | - | -4.76 % | $ 65.3 M | USA |
 |
Relmada Therapeutics
RLMD
|
2.66 M | $ 6.9 | -1.29 % | $ 272 M | USA |
 |
Rockwell Medical
RMTI
|
8.83 M | $ 0.96 | 0.84 % | $ 34.5 M | USA |
 |
SCYNEXIS
SCYX
|
1.69 M | $ 0.92 | 3.28 % | $ 45.9 M | USA |
 |
Solid Biosciences
SLDB
|
19.1 M | $ 7.74 | 3.34 % | $ 677 M | USA |
 |
Sonoma Pharmaceuticals
SNOA
|
27 K | $ 2.33 | -1.9 % | $ 2.89 M | USA |
 |
Tilray
TLRY
|
221 M | $ 6.66 | 1.68 % | $ 4.12 B | Canada |
 |
Veru
VERU
|
2.92 M | $ 2.4 | 4.8 % | $ 324 M | USA |
 |
Viatris
VTRS
|
18 B | $ 13.41 | -0.22 % | $ 16.1 B | USA |
 |
cbdMD
YCBD
|
2.4 M | $ 0.73 | -0.4 % | $ 3.15 M | USA |
 |
Zomedica Corp.
ZOM
|
1.47 M | - | -0.21 % | $ 98 M | USA |
 |
Zynerba Pharmaceuticals
ZYNE
|
120 K | - | - | $ 55.5 M | USA |
 |
Tricida
TCDA
|
11.3 M | - | - | $ 3.25 M | USA |
 |
TherapeuticsMD
TXMD
|
5.12 M | $ 2.2 | 10.0 % | $ 25.5 M | USA |